{"preliminary_commentary":{"by_channel":{"x_thread":9,"youtube":4,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03136627\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["tivozanib","nivolumab"]],"indication":"metastatic renal cell carcinoma","name":"TiNivo","nct_id":"NCT03136627","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=tinivo-nct03136627. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Tivozanib plus Nivolumab:Tivozanib will be administered once daily for 3 weeks followed by 1 week off. Nivolumab will be administered every 2 weeks starting on Day 1.","label":"Tivozanib (AV-951) plus Nivolumab","type":"EXPERIMENTAL"}],"collaborators":["Bristol-Myers Squibb"],"completion_date":{"date":"2021-06-18","type":"ACTUAL"},"conditions":["Carcinoma, Renal Cell"],"enrollment":{"count":28,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Tivozanib","otherNames":["AV-951"],"type":"DRUG"},{"name":"Nivolumab","otherNames":["Opdivo (anti-PD-1 monoclonal antibody)"],"type":"DRUG"}],"last_update":"2021-12-06","lead_sponsor":"AVEO Pharmaceuticals, Inc.","official_title":"A Phase 1b/2, Open-Label, Multi-Center Study of Tivozanib in Combination With Nivolumab in Subjects With Metastatic Renal Cell Carcinoma","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2017-12-21","type":"ACTUAL"},"primary_outcomes":[{"measure":"Maximum Tolerated Dose (MTD) of tivozanib administered orally in combination with Nivolumab in subjects with advanced renal cell carcinoma.","timeFrame":"28 days (1 Cycle)"}],"references":[{"citation":"Albiges L, Barthelemy P, Gross-Goupil M, Negrier S, Needle MN, Escudier B. TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma. Ann Oncol. 2021 Jan;32(1):97-102. doi: 10.1016/j.annonc.2020.09.021. Epub 2020 Sep 30.","pmid":"33010459","type":"DERIVED"}],"start_date":{"date":"2017-03-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC","url":"https://clinicaltrials.gov/study/NCT03136627"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/tinivo-nct03136627"}